Emergex obtains approval to commence Phase I trial of Covid-19 vaccine
Subject dosing in the trial to assess safety and tolerability of the vaccine will begin in January next year.
Switzerland
Latest in
Switzerland
AC Immune reports positive data from Alzheimer’s disease drug trial
Semorinemab was well-tolerated and had a tolerable safety profile in the Phase II trial.
Novartis’ Kymriah fails to meet primary goal in non-Hodgkin lymphoma trial
The safety profile of the drug in the Phase III BELINDA trial was in line with the already reported data.
Novartis reports positive data from Phase III DME trials of Beovu
Beovu showed a generally well-tolerated safety profile in Phase III KITE and KINGFISHER trials.
WHO launches Solidarity PLUS to assess three new drugs for Covid-19
An independent expert panel selected artesunate, imatinib and infliximab to potentially mitigate Covid-19-related death risk.
Roche’s Evrysdi boosts survival and motor function in SMA trial
Nearly 29% of infants could sit without needing support for five seconds by 12 months following treatment.
Polyphor’s balixafortide fails in late-stage breast cancer study
The failure also prompted Polyphor to carry out a strategic assessment about the future of the company.
Idorsia starts Phase III study to assess efficacy of heart attack drug
The study plans to enrol around 14,000 patients who are at high risk of recurrent acute myocardial infarction (AMI).